Varaico: Literature-Extracted Genetic Variants

Gene:KRAS
Variant:p.E49V
Back to variants list

KRAS

NM_004985.5:p.E49V

Associated Papers

Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.

Carnero-Gregorio M et al.

Genes, 2026

Aggressive Right-Sided Colon Cancer in a Young Adult: Triple-Whammy Mutations (POLE, KRAS, BRCA1/2) Highlight Emerging Genetic Associations.

Patel R et al.

Acg Case Reports Journal, 2026

Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.

Hekimoglu G et al.

Genes, 2026

Generation of Human Haematopoietic Model Cell Lines Revealed Distinct Replication Stress Tolerance Between Two Oncogenic KRAS Mutations, G12V and A146T.

Okuda M et al.

Biomolecules, 2026

Common gene mutations in 103 authenticated colorectal cancer cell lines.

Kranjec C et al.

Oncogenesis, 2026

41593049 (PubMed )
Supplement: 41389_2026_599_MOESM2_ESM.xlsx › Supplementary_Table_10

Tumor microenvironment changes after treatment with avelumab and immune-stimulating agent combinations in patients with advanced solid tumors.

Lermi NO et al.

Research Square, 2026

Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.

Ochman B et al.

International Journal of Molecular Sciences, 2026

RAS-variant allele frequency as a potential prognostic marker of overall survival in patients with metastatic colorectal cancer.

Nindra U et al.

Cancer Treatment and Research Communications, 2026

Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.

Zhang L et al.

Biorxiv : the Preprint Server for Biology, 2026

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.

Brown JR et al.

Blood, 2026

41055698 (PubMed )
Supplement: BLOOD_BLD-2024-027009-mmc5.xlsx › Sheet_1

Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.

Nakata E et al.

Cancer Science, 2026

41128349 (PubMed )
Supplement: CAS-117-156-s003.xlsx › Sheet1

Molecular basis of Rab43 inactivation by RN-Tre in endocytic trafficking unveils a general Rab-GAP recognition mechanism.

Wang J et al.

International Journal of Biological Macromolecules, 2026

Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.

Ogura N et al.

Jco Precision Oncology, 2026

Prognostic Significance of SOX9 and Its Combination With RAS and TP53 Mutations Following Colorectal Cancer Liver Metastasectomy.

Duan JL et al.

Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2025

Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s).

Wang SA et al.

Haematologica, 2025

Mathematical Modeling Quantifies "Just-Right" APC Inactivation for Colorectal Cancer Initiation.

Brunet Guasch M et al.

Cancer Research, 2025

A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.

Motta L et al.

Cancers, 2025

Acute promyelocytic leukemia with a rare TBL1XR1::RARA fusion and distinctive morphologic and phenotypic attributes.

Halloran P et al.

Journal of Hematopathology, 2025

Nucleotide Substitution Biases in Related Cancer Driver Genes.

Khadre A et al.

International Journal of Molecular Sciences, 2025

41465353 (PubMed )
Supplement: ijms-26-11903-s001.zip › Supplementary_Table_S3.xlsx › S3B

Age-Related Multigene Analysis of Colorectal Cancer Using Next-Generation Sequencing.

Kozlowska-Geller M et al.

Cancers, 2025

41463160 (PubMed )
Supplement: cancers-17-03909-s001.zip › cancers-3953905-supplementary.pdf

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.

Shi Y et al.

Signal Transduction and Targeted Therapy, 2025

41326340 (PubMed )
Supplement: 41392_2025_2481_MOESM1_ESM.docx

Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.

Lescuyer G et al.

The Journal of Molecular Diagnostics : Jmd, 2025

Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies.

Liu L et al.

Medcomm, 2025

41346570 (PubMed )
Supplement: MCO2-6-e70483-s002.xlsx › Tumour_cellularity

KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials.

Navarro-Jiménez M et al.

Npj Precision Oncology, 2025

Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer.

Haraguchi E et al.

International Journal of Cancer, 2025

40658108 (PubMed )
Supplement: supplement_1.pdf

Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.

Ianniello M et al.

Journal of Translational Medicine, 2025

Differential effects of KRAS G-domain and hypervariable region mutants on cancer phenotypes.

de Borja JAD et al.

Scientific Reports, 2025

Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

Hamza A et al.

British Journal of Cancer, 2025

40931129 (PubMed )
Supplement: 41416_2025_3183_MOESM4_ESM.xlsx › S4B_Amino-acid_substitions

Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.

Li Y et al.

British Journal of Haematology, 2025

40958529 (PubMed )
Supplement: supplement_1.zip › Table_S3.xlsx › Sheet1

Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemia.

Newman H et al.

Hemasphere, 2025

41306327 (PubMed )
Supplement: HEM3-9-e70269-s013.xlsx › Supplemental_Table_5_-_SSVs

Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.

Yang J et al.

Translational Lung Cancer Research, 2025

41234595 (PubMed )
Supplement: tlcr-14-10-4235-supplementary.pdf

Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer.

Yano K et al.

Scientific Reports, 2025

Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.

Umeda M et al.

Blood, 2025

40700635 (PubMed )
Supplement: BLOOD_BLD-2025-028993-mmc2.xlsx › Supplementary_Table_6

Functional Analysis of Rare RAS Variants of Unknown Significance.

Park S et al.

Cancer Research Communications, 2025

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.

Kavgaci G et al.

Molecular Oncology, 2025

The Impact of RAS/BRAF Mutation on Pathological Complete Response After Total Neoadjuvant Therapy in Rectal Cancer.

Aboelmaaty S et al.

Annals of Surgical Oncology, 2025

Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC.

Gibbs P et al.

Clinical Colorectal Cancer, 2025

Analysis of IDH1 and IDH2 mutations as causes of the hypermethylator phenotype in colorectal cancer.

Ward JC et al.

The Journal of Pathology, 2025

The KRAS p.Ala146Thr mutation promotes the proliferation of colorectal cancer cells via CDK1-mediated ERK signaling.

Li W et al.

Cancer Genetics, 2025

1–50 of 860 papers
Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."